Maria Caterina Rotiroti, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytokine-Induced Killer Cells | 2 | 2022 | 6 | 0.920 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2023 | 1469 | 0.770 |
Why?
|
| Leukemia, Experimental | 1 | 2020 | 225 | 0.690 |
Why?
|
| Cell Transplantation | 1 | 2020 | 472 | 0.610 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2023 | 3613 | 0.530 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2023 | 2549 | 0.480 |
Why?
|
| Gangliosides | 2 | 2022 | 132 | 0.380 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 1784 | 0.330 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5305 | 0.240 |
Why?
|
| Logic | 1 | 2023 | 40 | 0.210 |
Why?
|
| Immunotherapy | 2 | 2022 | 4650 | 0.200 |
Why?
|
| Interleukin-3 | 1 | 2023 | 425 | 0.200 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 226 | 0.170 |
Why?
|
| Transposases | 1 | 2020 | 104 | 0.170 |
Why?
|
| Brain Stem Neoplasms | 1 | 2022 | 190 | 0.170 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 425 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 2 | 2023 | 940 | 0.150 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2017 | 36 | 0.140 |
Why?
|
| Astrocytoma | 1 | 2022 | 775 | 0.140 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 1827 | 0.130 |
Why?
|
| Gene Transfer Techniques | 1 | 2020 | 1206 | 0.120 |
Why?
|
| Mice, SCID | 1 | 2020 | 2626 | 0.120 |
Why?
|
| T-Lymphocytes | 5 | 2023 | 10194 | 0.120 |
Why?
|
| Neuroblastoma | 1 | 2022 | 1250 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 3602 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 1334 | 0.100 |
Why?
|
| Histones | 1 | 2022 | 2580 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 1640 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5246 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 3734 | 0.080 |
Why?
|
| Glioma | 1 | 2022 | 3455 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2022 | 1351 | 0.060 |
Why?
|
| Leukemia, B-Cell | 1 | 2023 | 84 | 0.050 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2022 | 86 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2023 | 23441 | 0.040 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2022 | 263 | 0.040 |
Why?
|
| Animals | 3 | 2022 | 168441 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 18247 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 30045 | 0.040 |
Why?
|
| Mice | 2 | 2022 | 81509 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2017 | 545 | 0.030 |
Why?
|
| Humans | 9 | 2023 | 761423 | 0.030 |
Why?
|
| Neoplasms | 1 | 2023 | 22164 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2020 | 64651 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2017 | 548 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2022 | 2203 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 3076 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2023 | 3541 | 0.020 |
Why?
|
| Child | 3 | 2023 | 80162 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3874 | 0.020 |
Why?
|
| Recurrence | 1 | 2021 | 8469 | 0.020 |
Why?
|
| Binding Sites | 1 | 2017 | 6055 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2017 | 5439 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 16979 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2022 | 10441 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2022 | 9418 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 9179 | 0.020 |
Why?
|
| Protein Binding | 1 | 2017 | 9352 | 0.010 |
Why?
|
| Gene Expression | 1 | 2017 | 7584 | 0.010 |
Why?
|
| Disease Progression | 1 | 2021 | 13502 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 9277 | 0.010 |
Why?
|
| Aged | 2 | 2023 | 169235 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 220826 | 0.000 |
Why?
|
| Adult | 1 | 2021 | 221148 | 0.000 |
Why?
|